Salim Syed
Stock Analyst at Mizuho
(1.80)
# 3,289
Out of 4,984 analysts
75
Total ratings
43.33%
Success rate
-0.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $1.95 | +617.95% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $49.76 | +68.81% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $143.68 | +17.62% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $273.09 | +2.53% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $110.86 | +5.54% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $6.82 | +222.58% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $31.23 | +421.93% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $11.51 | +56.39% | 4 | Aug 16, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $18.43 | +84.48% | 1 | Apr 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $61.19 | +61.79% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $51.49 | +2.93% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.36 | +1,444.12% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $20.55 | +75.18% | 1 | Nov 16, 2022 |
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $1.95
Upside: +617.95%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $49.76
Upside: +68.81%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $143.68
Upside: +17.62%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $273.09
Upside: +2.53%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $110.86
Upside: +5.54%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $6.82
Upside: +222.58%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $31.23
Upside: +421.93%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $11.51
Upside: +56.39%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $18.43
Upside: +84.48%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $61.19
Upside: +61.79%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $51.49
Upside: +2.93%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.36
Upside: +1,444.12%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $20.55
Upside: +75.18%